Rigor in science, confidence in clinical decisions

A track record of innovation and scientific collaboration means we excel at translating our best-in-class scientific research and data into clinically actionable findings. Our spirit of sharing data and collaboration weaves throughout our achievements. Whether it’s being the first to offer clinical exome sequencing in 2011, first to offer BRCA1/2-related testing gene panels after the 2013 Supreme Court gene patent decision, or first to offer paired tumor/germline testing in 2017—scientific excellence and doing what’s right for patient care remain vital to what we do.